Optimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson's Drug Candidate GT-02287
Chardan Capital Reiterates Buy on Gain Therapeutics, Maintains $6 Price Target
Gain Therapeutics Analyst Ratings
Buy Rating for Gain Therapeutics Backed by Strong Preclinical Data and Promising Parkinson's Candidate GT-02287
Buy Rating Affirmed: Gain Therapeutics' Promising GT-02287 Advances Towards Key Clinical Milestones in Parkinson's Disease Treatment
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX), Humana (HUM) and Boston Scientific (BSX)
Gain Therapeutics (GANX) Gets a Buy From BTIG
Buy Rating Affirmed: Gain Therapeutics' GT-02287 Shows Promise in Parkinson's Disease Pipeline
HC Wainwright & Co. Maintains Buy on Gain Therapeutics, Lowers Price Target to $9
Gain Therapeutics Analyst Ratings
Buy Rating on Gain Therapeutics Backed by Promising Parkinson's Candidate GT-02287 and Strengthened Financial Position
Promising Clinical Trials and Financial Outlook Boost Gain Therapeutics: A Comprehensive Buy Rating Analysis
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Gain Therapeutics (GANX)
Promising Therapeutic Approaches and Financial Stability Bolster Buy Rating for Gain Therapeutics
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Gain Therapeutics (GANX)
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $10 Price Target
Gain Therapeutics Analyst Ratings
Gain Therapeutics (GANX) Gets a Buy From H.C. Wainwright
Gain Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Seagen (SGEN) and Gain Therapeutics (GANX)
No Data